# US 10,245,239 B2 · Astaxanthin anti-inflammatory synergistic combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,245,239 B2
- Document ID: US10245239B2
- Status: Granted
- Kind: B2
- Application number: 15/865,407
- Filed: 2018-01-09
- Published: 2018-05-31
- Granted: 2019-04-02
- Earliest claimed: 2013-03-19
- Assignees: Lycored Ltd.
- Applicants: Lycored Ltd.
- Inventors: Rachel Levy; Nurit Hadad; Tanya Sedlov; Morris Zelkha
- Web page: https://patentgrep.com/patent/US10245239B2

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/01: Hydrocarbons
- A61K 31/015: carbocyclic
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions having synergistic combinations of astaxanthin with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. Compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.

## Claims

### Claim 1

A composition comprising: lycopene, astaxanthin and carnosic acid, wherein the molar concentration ratio of astaxanthin to carnosic acid is from 1:1 to 1:10.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said composition further comprises phytoene, phytofluene, beta-carotene, a tocopherol, phytosterols, or any combination thereof.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising lutein.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said composition is an oral composition.

### Claim 5 (depends on 1)

The composition of claim 1, further comprising a nutraceutical or a pharmaceutical acceptable excipient.

### Claim 6

A method of treating a subject afflicted with inflammation, comprising the step of administering to said subject a therapeutically effective amount of a composition comprising lycopene, astaxanthin and carnosic acid, wherein the molar concentration ratio of astaxanthin to carnosic acid is from 1:1 to 1:10, thereby treating a subject afflicted with inflammation.

### Claim 7 (depends on 6)

The method of claim 6, wherein the composition is an oral composition.

### Claim 8 (depends on 6)

The method of claim 6, wherein the composition further comprises a nutraceutical or a pharmaceutical acceptable excipient.

### Claim 9 (depends on 6)

The method of claim 6, wherein the composition further comprises lutein, phytoene, phytofluene, beta-carotene, a tocopherol, phytosterols, or any combination thereof.